A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).

Authors: Rahul Raj Aggarwal, Michael Thomas Schweizer, Christopher H. Chay, Omkar Marathe, Emilio Araujo-Mino, David Morris, David M. Nanus, Mohit Narang, Alexander I. Spira, Ian D. Schnadig, Sarah Attwell, Emily Johnson, Philip Wegge, Vandy Xu, Helena Zhu, Alissa McGuire, Margo Snyder, Michael Sweeney, Sanjay Lakhotia, Joshi J. Alumkal

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps5123

Source: Full article

---

Abstract

TPS5123